China's NMPA Accepts NCX 470 NDA for Review in Open-Angle Glaucoma and Ocular Hypertension
核心洞察
China's National Medical Products Administration (搜索) accepted for review the NCX 470 New Drug Application submitted in August 2026 by licensee Ocumension Therapeutics (搜索).
NCX 470 is a nitric oxide-donating bimatoprost eye drop that lowers intraocular pressure through two distinct pathways in open-angle glaucoma (搜索) or ocular hypertension (搜索).
The Chinese review is expected to take 12 to 18 months, with a decision anticipated after the U.S. FDA's 30 April 2027 PDUFA date.
China's National Medical Products Administration (搜索) (NMPA) has accepted for review the New Drug Application (NDA) for NCX 470, Nicox SA (搜索)'s investigational nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure (IOP) in patients with open-angle glaucoma (搜索) or ocular hypertension (搜索). The acceptance, confirmed to Nicox's exclusive Chinese licensee Ocumension Therapeutics (搜索), initiates the NMPA's examination of the dossier and moves the program one formal review cycle closer to a potential approval in one of the world's largest ophthalmology markets.
The application was submitted in August 2026 and accepted for review on 10 September 2026, according to Nicox. The company announced the milestone on 11 September 2026 from Sophia Antipolis, France.
"The acceptance for review of the NCX 470 NDA in China initiates the examination process and is another key step towards its commercialisation in this territory. We look forward to continuing to work with the Ocumension team as they prepare for a future launch," said Gavin Spencer, Chief Executive Officer of Nicox.
A Two-Pathway Mechanism Built on Phase 3 Data
NCX 470 (bimatoprost grenod), referred to as OT-301 by Ocumension, is a single molecule that incorporates Nicox's proprietary nitric oxide (NO)-donating research platform with bimatoprost. The design releases both bimatoprost and NO into the eye to lower IOP through two different pathways.
Bimatoprost, a prostaglandin analog (PGA), provides the uveoscleral outflow mechanism, while NO — a small, naturally occurring signalling molecule that regulates IOP through activation of soluble guanylate cyclase (搜索) (sGC) — adds IOP-lowering efficacy by enhancing aqueous humor drainage via a different mechanism of action. In the DENALI trial, NCX 470 0.1% met non-inferiority against latanoprost 0.005%, with mean IOP reductions from baseline reaching into the 7-plus mmHg range across measured timepoints.
The China filing draws on the existing clinical package rather than requiring a separate local trial program from scratch. NCX 470 has completed two Phase 3 trials designed to fulfil regulatory requirements for safety and efficacy in support of NDA submissions in both the U.S. and China: Mont Blanc and Denali. Nicox states that both trials were positive and met the efficacy endpoints necessary for NDA submission. NCX 470 remains an investigational product and has not been approved by the FDA.
Review Timeline and U.S. Sequencing
There is no fixed period for approval of a pharmaceutical product in China, but the review process typically takes 12 to 18 months following submission. Nicox expects the Chinese decision to come after the U.S. FDA's decision, for which the agency has assigned a PDUFA date of 30 April 2027. A U.S. launch is expected in H2 2027, subject to NDA approval. NMPA's 2022 registration provisions allow for a parallel review process independent of FDA action, so Chinese approval is not contingent on U.S. clearance.
Japan Phase 3 clinical trials of NCX 470 are ongoing, with results pending.
Commercial Terms and Launch Readiness
Ocumension holds rights to develop and commercialise NCX 470 in the Chinese, Korean and Southeast Asian markets. The company has paid Nicox license fees of €18 million, contributed 50% of the Denali clinical trial costs, and is one of Nicox's principal shareholders. Nicox will receive tiered royalties on Ocumension's sales of NCX 470 ranging from 6% to 12%.
Ocumension already has an ophthalmology sales force in place throughout China, which Nicox describes as positioning the licensee for a rapid launch of NCX 470 if approval is granted. Whether Nicox can convert an NMPA green light into commercial value in China, and on what economic terms, remains the open question for the small French biotech, whose ability to sustain operations through the review period is a key consideration given the gap between NDA acceptance and commercial revenue in a new geography.
Broader Ophthalmology Portfolio
Beyond NCX 470, Nicox's portfolio includes VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb (搜索) and commercially available in the U.S. and more than 15 other territories. The company also generates revenue from ZERVIATE in allergic conjunctivitis (搜索), licensed in multiple geographies including to Harrow, Inc. in the U.S. and to Ocumension Therapeutics (搜索) in China and the majority of Southeast Asian markets. Nicox has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 (搜索) inhibitor, partnered with Glaukos. Nicox is listed on Euronext Growth Paris under the ticker ALCOX.